A GLP-1 receptor agonist. This profile cites a Trulicity label.↗
Citation markers ↗ open the public records supporting the adjacent statements.
Correction · September 15, 2026
We refreshed this profile's label citation to the reviewed SPL version 62, published 2026-08-10. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope. 1
U.S. label record. The cited DailyMed label identifies Dulaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Three selected randomized reports cover cardiovascular events in older adults with type 2 diabetes, glycemic outcomes in youths, and glycemic and kidney measures in adults with chronic kidney disease. This overview does not cover the full AWARD program or all later analyses.↗↗↗
What the reviewed sources report
REWIND reported fewer composite cardiovascular events with dulaglutide; all-cause mortality did not differ significantly. AWARD-PEDS reported improved glycemic control without a between-group BMI benefit. AWARD-7 studied a kidney-disease population, with glycemic control as its primary outcome.↗↗↗
What remains unresolved?
What do longer-term studies establish for populations and outcomes outside these three selected reports?↗↗↗
How do later trial analyses relate to their original cohorts, and which findings have independent replication?↗↗↗
The label covers glycemic control with diet and exercise in adults and children aged ten years and older with type 2 diabetes. Its cardiovascular indication concerns adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Label: 1 ↗
Which safety limits matter?
The boxed warning reports thyroid C-cell tumors in rats, with uncertain human relevance. Contraindications include a personal or family history of medullary thyroid carcinoma, MEN 2 and serious hypersensitivity. Other warnings include pancreatitis, hypoglycemia with insulin or insulin secretagogues, kidney injury from volume depletion, severe gastrointestinal reactions, retinopathy complications, gallbladder disease and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 0be61134741cd12e32e7ea35d42b7ad3d11a0a333b31e08005cf499692d46779. Extracted XML SHA-256: 2a790740cae6415ba5160d0c578d599e26decb426a6f5c59d99803bb53b227d5.
FDA’s 2022 review describes study GBGC in 154 participants aged 10–17 with type 2 diabetes. It compared two dulaglutide groups with placebo during a 26-week blinded period, followed by a 26-week open-label period. The extension is not another independent randomized trial. FDA PDF pp. 5, 6 ↗
More findings and the sources behind them
Selected sections of the November 16, 2022 FDA pediatric supplement review, separate from the original adult EMA assessment and later regulatory changes.
The primary result concerned glucose control
The review supports a reduction in HbA1c versus placebo at week 26. Its prose and Table 2 disagree on the pooled point estimate, so this account does not select one silently. The primary endpoint was not weight loss or cardiovascular events. FDA PDF pp. 7, 8 ↗
Safety findings retain the accompanying-treatment context
Gastrointestinal events were the most common treatment-emergent adverse events. FDA observed the greatest hypoglycemia risk among participants also using insulin. This small pediatric program cannot rule out uncommon or longer-term harms. FDA PDF pp. 9, 12 ↗
The recommendation was specific to this supplement
The reviewer supported extending the glycemic-control indication to patients aged ten and older and discharging one pediatric study requirement. A separate requirement covering higher strengths remained outstanding in this November 2022 memo; its present status needs separate verification. FDA PDF pp. 12, 13 ↗
What remains to be checked
Reconcile the pooled point-estimate discrepancy against the statistical review and trial publication.
Verify subsequent pediatric requirements and the current product label; the historical memo is not a current prescribing summary.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
The original efficacy program focused on glycemic control
EMA’s 2014 review found HbA1c reductions across trials with different background therapies and comparators. Changes from baseline and between-group differences are different measures; they should not be pooled into a single headline effect. EMA PDF pp. 165, 166 ↗
More findings, study links and document coverage
Long exposure was much less common than any exposure
The phase 2/3 program included 4,006 participants exposed to dulaglutide, but only 642 for at least 78 weeks and 157 for at least 104 weeks. EMA identified this as a limitation for a treatment intended for chronic use. EMA PDF pp. 168 ↗
Background therapy changes the safety context
The review reports substantially greater hypoglycemia risk when dulaglutide was studied alongside insulin or a sulfonylurea. Comparing raw adverse-event rates without the accompanying regimen can mislead. EMA PDF pp. 168 ↗
This historical review precedes later evidence
The 2014 assessment described a cardiovascular outcomes trial as ongoing. It should be read alongside subsequent outcome studies and the separate 2022 pediatric FDA source note, not treated as the latest statement of all available evidence. EMA PDF pp. 169 ↗
Selected sections read in 1 of 22 inventoried documents; 21 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
Selected English EMA PDFs from the retained September 15, 2026 title-matched document feed, plus independently retrieved FDA approval-package documents where listed. Candidate entries are not verified product/application matches. This is a bounded inventory, not a complete FDA, national or worldwide source search. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
PDF identity verified independently of the feed. Selected sections reviewed; historical findings are not a current prescribing summary.
Verified: Trulicity · EMEA/H/C/002825 · Document dated 2014-09-25. Identity checked on PDF pp. 1, 2.
Identity and selected clinical design, efficacy, safety and benefit-risk sections only. One-based PDF file pages; unlisted pages have not been appraised. The date identifies the selected review within any compiled approval package.
Retrieved 2026-09-19. Read PDF pages: 1, 2, 165, 166, 167, 168, 169 of 172. SHA-256: 87d3ed40c84f3e768d08baa718d5fb6da45337587585acba88defb4c453b72af.
Feed-listed application (not a verified association): EMEA/H/C/002825.
European medicine records · 1 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: dulaglutide. EMA record ↗
Marketing authorisation: 2014-11-21. EMA metadata last updated 2026-01-30. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
1286 retrieved · 3 included · 0 excluded · 1283 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Dulaglutide"[Title/Abstract] OR "Trulicity"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Showing 25 of 1286 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 35658022 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT02963766.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 31189511 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01394952.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 29910024 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01621178.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42730869 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42729958 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42726083 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42706739 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42692277 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42687799 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42682267 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42652097 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42645931 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42629417 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42626264 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42624955 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42623541 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42618994 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42618811 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42609010 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42608321 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42607855 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 30000038 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42594084 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42584027 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42575344 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA BLA125469 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: DULAGLUTIDE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/002825 — include: EMA feed product Trulicity; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
23 retrieved · 14 included · 0 excluded · 9 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 23 of 23 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 3547 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-PSUSA-10311-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 7481 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Medicine overview
EMA 15349 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 28747 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - All Authorised presentations
EMA 29560 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Public assessment report
EMA 33131 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Risk-management-plan summary
EMA 39535 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-PSUSA-00010311-201709 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 45943 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-2825-II-0040 : EPAR - Assessment report - Variation
EMA 50024 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-2825-X-0045 : EPAR - Assessment report - Variation
EMA 51787 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-PSUSA-10311-202009 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)
EMA 58037 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-2825-II-0065 : EPAR - Assessment report - Variation
EMA 3409 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 72360 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Procedural steps taken and scientific information after authorisation
EMA 11584 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Product information
EMA 35491 — not screened: Title-name match awaiting identity and document review. CHMP summary of positive opinion for Trulicity
EMA 45471 — not screened: Title-name match awaiting identity and document review. CHMP post-authorisation summary of positive opinion for Trulicity (II-40)
EMA 57411 — not screened: Title-name match awaiting identity and document review. CHMP post-authorisation summary of opinion for Trulicity (II-65)
EMA 57625 — not screened: Title-name match awaiting identity and document review. P/0409/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity), (EMEA-000783-PIP01-09-M06)
EMA 50586 — not screened: Title-name match awaiting identity and document review. P/0175/2020: EMA decision of 13 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity), (EMEA-000783-PIP01-09-M05)
EMA 14233 — not screened: Title-name match awaiting identity and document review. P/0227/2016: EMA decision of 26 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide
(Trulicity), (EMEA-000783-PIP01-09-M04)
EMA 12783 — not screened: Title-name match awaiting identity and document review. P/0017/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity), (EMEA-000783-PIP01-09-M03)
EMA 18730 — not screened: Title-name match awaiting identity and document review. P/0039/2014: EMA decision of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (EMEA-000783-PIP01-09-M01)
EMA 31033 — not screened: Title-name match awaiting identity and document review. P/0105/2015: EMA decision of 29 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity) (EMEA-000783-PIP01-09-M02)
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
147 retrieved · 0 included · 0 excluded · 147 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 147 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT05377333 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06500143 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05140694 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03204396 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07276763 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03363906 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06901648 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05946148 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06779929 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07537088 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05990374 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01511393 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06611904 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05478707 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01558271 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05564039 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07398222 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07619495 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07313813 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04189848 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05492305 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01001104 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01253304 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06120556 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05348122 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Dulaglutide?
Three selected randomized reports cover cardiovascular events in older adults with type 2 diabetes, glycemic outcomes in youths, and glycemic and kidney measures in adults with chronic kidney disease. This overview does not cover the full AWARD program or all later analyses.123
Bottom line from this bounded source set
REWIND reported fewer composite cardiovascular events with dulaglutide; all-cause mortality did not differ significantly. AWARD-PEDS reported improved glycemic control without a between-group BMI benefit. AWARD-7 studied a kidney-disease population, with glycemic control as its primary outcome.123
Reviewed study record
REWIND: cardiovascular outcomes
Design
A blinded randomized placebo-controlled trial followed participants for a median of 5.4 years.1
Population
The trial enrolled 9,901 adults aged at least 50 with type 2 diabetes and cardiovascular disease or risk factors.1
Outcomes reported
The primary cardiovascular composite occurred in 12.0% with dulaglutide versus 13.4% with placebo (hazard ratio 0.88; 95% CI 0.79–0.99). Gastrointestinal adverse events were more frequent with dulaglutide.1
Limitations
The composite combines different outcomes and does not imply improvement in every component. All-cause mortality was not significantly different; these results do not establish effects in people without type 2 diabetes.1
Reviewed study record
AWARD-PEDS: glycemic control in youths
Design
A blinded randomized placebo-controlled study evaluated a 26-week primary endpoint, followed by an open-label extension.2
Population
The trial randomized 154 participants aged 10 to under 18 with type 2 diabetes.2
Outcomes reported
Glycated hemoglobin decreased in the dulaglutide groups and increased with placebo. BMI change did not differ between groups; gastrointestinal adverse events were more frequent with dulaglutide.2
Limitations
The primary outcome was glycemic control, not cardiovascular events or long-term complications. The short blinded period limits longer-term conclusions; PubMed links subsequent correspondence.2
Reviewed study record
AWARD-7: diabetes with chronic kidney disease
Design
An open-label randomized trial compared dulaglutide with insulin glargine, with insulin lispro in all groups, over 52 weeks.3
Population
The study randomized 577 adults with type 2 diabetes and stage 3–4 chronic kidney disease.3
Outcomes reported
Dulaglutide met the prespecified noninferiority criterion for glycated hemoglobin change at 26 weeks. At 52 weeks, estimated filtration rates were higher with dulaglutide; nausea and diarrhea were more frequent.3
Limitations
Kidney measures were secondary outcomes. This trial cannot establish a general prevention claim for kidney failure or isolate the effects of background insulin treatment.3
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(19)31149-3. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2204601. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s2213-8587(18)30104-9. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Dulaglutide?
U.S. label record. The cited DailyMed label identifies Dulaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
The cited status sources were checked through September 15, 2026. This answer changes only through the profile’s visible version and correction history.
All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
A phase value is unavailable here for 6 selected records; this is not counted as “no phase.”
A status value is unavailable here for 5 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
14 of 38 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 12Research Support, Non-U.S. Gov't 3Case Reports 2Letter 2Randomized Controlled Trial 2Comment 1Comparative Study 1Multicenter Study 1Review 1
Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
1
FDA Federal Register documents
1
DailyMed SPL versions
39
Canonical profile
Published
Profile structured data
Published
Linked dated records
91
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
We refreshed this profile's label citation to the reviewed SPL version 62, published 2026-08-10. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
PeptideScanner retained ClinicalTrials.gov record NCT06851962 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT07313813 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was dulaglutide.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
The cited DailyMed label identifies Dulaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PeptideScanner retained ClinicalTrials.gov record NCT06851962 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was dulaglutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07313813 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was dulaglutide.↗
PeptideScanner retained ClinicalTrials.gov record NCT05478707 at 2026-08-13T05:54:14.860Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was dulaglutide.↗
DailyMed lists Structured Product Labeling version 62 for the reviewed Dulaglutide label family with a published date of 2026-08-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
PeptideScanner retained ClinicalTrials.gov record NCT06739122 at 2026-08-13T05:52:27.010Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was dulaglutide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41988866 at 2026-08-10T18:13:46.880Z. PubMed recorded a metadata revision date of 2026-07-15 and an Entrez history date of 2026-04-16. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT07417631 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was dulaglutide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 37743669 at 2026-08-10T18:13:32.327Z. PubMed recorded a metadata revision date of 2026-07-06 and an Entrez history date of 2023-09-25. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38954432 at 2026-07-30T16:14:08.766Z. PubMed recorded a metadata revision date of 2026-06-22 and an Entrez history date of 2024-07-02. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 39718468 at 2026-07-30T16:14:08.915Z. PubMed recorded a metadata revision date of 2026-06-20 and an Entrez history date of 2024-12-24. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38600796 at 2026-07-30T16:14:06.917Z. PubMed recorded a metadata revision date of 2026-06-19 and an Entrez history date of 2024-04-11. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38715179 at 2026-07-30T16:14:06.944Z. PubMed recorded a metadata revision date of 2026-06-18 and an Entrez history date of 2024-05-07. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗